| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Dose escalation of a curcuminoid formulation. | BMC Complement Altern Med | 2006 | 3.59 |
| 2 | Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. | Cancer Prev Res (Phila) | 2011 | 1.57 |
| 3 | Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. | Am J Clin Nutr | 2003 | 0.98 |
| 4 | Fenretinide: a prototype cancer prevention drug. | Expert Opin Investig Drugs | 2003 | 0.92 |
| 5 | Methyl selenocysteine: single-dose pharmacokinetics in men. | Cancer Prev Res (Phila) | 2011 | 0.88 |
| 6 | Development of novel cancer chemopreventive agents in Europe--neglected Cinderella or rising phoenix? A critical commentary. ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18-20, 2005. | Eur J Cancer | 2006 | 0.77 |
| 7 | Inhibition of mitogen-activated protein kinase activity of human lymphocytes after oral administration of Oltipraz. | Mol Cancer Ther | 2002 | 0.77 |